Literature DB >> 27621503

Clofarabine and Cytarabine Regimen for Acute Myeloid Leukemia.

Kristin V Ho1, Dominic A Solimando1, J Aubrey Waddell1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2015        PMID： 27621503      PMCID： PMC4750846          DOI： 10.1310/hpj5011-969

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  24 in total

1.  Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.

Authors:  Edward Agura; Barry Cooper; Houston Holmes; Estil Vance; Robert Brian Berryman; Christopher Maisel; Sandy Li; Giovanna Saracino; Mirjana Tadic-Ovcina; Joseph Fay
Journal:  Oncologist       Date:  2011-01-27

2.  Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

Authors:  Hiroto Inaba; Jeffrey E Rubnitz; Elaine Coustan-Smith; Lie Li; Brian D Furmanski; Gerard P Mascara; Kenneth M Heym; Robbin Christensen; Mihaela Onciu; Sheila A Shurtleff; Stanley B Pounds; Ching-Hon Pui; Raul C Ribeiro; Dario Campana; Sharyn D Baker
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

Review 3.  The effects of impaired liver function on the elimination of antineoplastic agents.

Authors:  G Koren; K Beatty; A Seto; T R Einarson; M Lishner
Journal:  Ann Pharmacother       Date:  1992-03       Impact factor: 3.154

4.  AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.

Authors:  Todd M Cooper; Todd A Alonzo; Robert B Gerbing; John P Perentesis; James A Whitlock; Jeffrey W Taub; Terzah M Horton; Alan S Gamis; Soheil Meshinchi; Michael R Loken; Bassem I Razzouk
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

5.  Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.

Authors:  Stefan Faderl; Varsha Gandhi; Susan O'Brien; Peter Bonate; Jorge Cortes; Elihu Estey; Miloslav Beran; William Wierda; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Francis J Giles; Min Du; Monica Kwari; Michael Keating; William Plunkett; Hagop Kantarjian
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

6.  A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  Stefan Faderl; Farhad Ravandi; Xuelin Huang; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Gautam Borthakur; Srdan Verstovsek; Deborah A Thomas; Monica Kwari; Hagop M Kantarjian
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

Review 7.  Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.

Authors:  P E Kintzel; R T Dorr
Journal:  Cancer Treat Rev       Date:  1995-01       Impact factor: 12.111

8.  Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.

Authors:  M G Martin; G L Uy; E Procknow; K Stockerl-Goldstein; A Cashen; P Westervelt; C N Abboud; K Augustin; J Luo; J F DiPersio; R Vij
Journal:  Bone Marrow Transplant       Date:  2009-01-12       Impact factor: 5.483

Review 9.  Hepatotoxicity of chemotherapy.

Authors:  Justin Floyd; Irfan Mirza; Bradley Sachs; Michael C Perry
Journal:  Semin Oncol       Date:  2006-02       Impact factor: 4.929

10.  Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

Authors:  Stefan Faderl; Meir Wetzler; David Rizzieri; Gary Schiller; Madan Jagasia; Robert Stuart; Siddhartha Ganguly; David Avigan; Michael Craig; Robert Collins; Michael Maris; Tibor Kovacsovics; Stuart Goldberg; Karen Seiter; Parameswaran Hari; Jochen Greiner; Norbert Vey; Christian Recher; Farhad Ravandi; Eunice S Wang; Michael Vasconcelles; Dirk Huebner; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544
View more
  1 in total

1.  Successful combination chemotherapy involving clofarabine, cyclophosphamide, and etoposide for pediatric relapsed acute myeloid leukemia: A case report.

Authors:  Sachio Fujita; Ryosuke Matsuno; Naoko Kawabata; Yumiko Sugishita; Ryota Kaneko; Masaya Koganesawa; Kosuke Akiyama; Daisuke Toyama; Shohei Yamamoto
Journal:  SAGE Open Med Case Rep       Date:  2021-05-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.